The US FDA has recently proposed a new draft framework that enables pharma manufacturers to add software to a drug label if they can demonstrate that the software adds clinical benefit to the drug.

A U.S. federal judge in Texas on Thursday blocked a rule that expanded the amount of information companies have to turn over when seeking a merger review, saying it exceeded the Federal Trade ...